Cell Therapeutics names new president of European operations
In her new role as president of Cell Therapeutics (CTI) Europe, Dr Waters, will accelerate the launch of Ap(3)ana, an organization that will seek to integrate new technologies
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).